Atrium Reports 3Q 2026 Financials and First Patient Dosed in PRKAG2 Trial
Atrium Therapeutics dosed the first patient in its cardiac RNA therapeutic trial for PRKAG2 syndrome, reversing glycogen accumulation in nonclinical models. The company closed a $50 million private placement, extending its cash runway through 2028.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed